Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KARAM C MOUNZER

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1265571152
CMS profile
239323
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$81,872.38

159 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ViiV Healthcare Company $41,755.96 81
Gilead Sciences, Inc. $22,609.58 46
Janssen Products, LP $10,569.48 6
Janssen Scientific Affairs, LLC $4,606.16 8
Merck Sharp & Dohme LLC $1,986.22 6
Theratechnologies Inc. $170.22 4
Janssen Biotech, Inc. $71.46 4
ABBVIE INC. $68.30 3
Janssen Pharmaceuticals, Inc $35.00 1

Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KARAM C MOUNZER

NPI 1265571152 · CMS profile ID 239323

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265571152?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KARAM C MOUNZER, NPI 1265571152, CMS profile ID 239323. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265571152?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). KARAM C MOUNZER, NPI 1265571152, CMS profile ID 239323. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265571152?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
KARAM C MOUNZER, NPI 1265571152, CMS profile ID 239323, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1265571152?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

159 matching records · $81,872.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 159 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 159.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $125.0009/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025505653 CMS
ViiV Healthcare Company $3,900.0009/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000850849 CMS
ViiV Healthcare Company $441.8009/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000851557 CMS
ViiV Healthcare Company $66.8709/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000851007 CMS
Janssen Biotech, Inc. $18.3109/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988333065 CMS
Gilead Sciences, Inc. $22.3308/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025731427 CMS
ViiV Healthcare Company $5.2208/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000851947 CMS
ViiV Healthcare Company $22.0408/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000852381 CMS
ViiV Healthcare Company $4.9408/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000850961 CMS
ViiV Healthcare Company $9.0008/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000852013 CMS
ViiV Healthcare Company $5.4007/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000850895 CMS
Theratechnologies Inc. $14.6807/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022758681 CMS
ViiV Healthcare Company $9.1807/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000852471 CMS
Janssen Biotech, Inc. $22.0407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988333073 CMS
Janssen Products, LP $3,535.0007/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988006389 CMS
Gilead Sciences, Inc. $2,450.0006/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035831429 CMS
Gilead Sciences, Inc. $122.2606/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025511837 CMS
Gilead Sciences, Inc. $22.3406/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025731129 CMS
ViiV Healthcare Company $15.8906/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000851381 CMS
Janssen Products, LP $833.4006/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988006429 CMS
Janssen Products, LP $68.5406/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988006423 CMS
ViiV Healthcare Company $20.5706/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000850811 CMS
Gilead Sciences, Inc. $5.5306/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026122749 CMS
Gilead Sciences, Inc. $5.0006/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025491757 CMS
Gilead Sciences, Inc. $26.2006/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025491761 CMS
Gilead Sciences, Inc. $40.0006/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025491763 CMS
ABBVIE INC. $22.3405/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997959785 CMS
ViiV Healthcare Company $7.6105/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000851997 CMS
Janssen Biotech, Inc. $10.5405/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988333089 CMS
ViiV Healthcare Company $22.1005/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000851023 CMS
Merck Sharp & Dohme LLC $32.8005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048476477 CMS
Janssen Scientific Affairs, LLC $4,000.0005/12/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988437789 CMS
Janssen Scientific Affairs, LLC $65.0005/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988437798 CMS
Janssen Scientific Affairs, LLC $301.3905/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988437807 CMS
Janssen Scientific Affairs, LLC $36.5805/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988437827 CMS
Janssen Scientific Affairs, LLC $17.5605/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988437835 CMS
Janssen Scientific Affairs, LLC $52.7405/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988437847 CMS
Janssen Scientific Affairs, LLC $17.5605/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988437857 CMS
Janssen Scientific Affairs, LLC $115.3305/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988437817 CMS
ViiV Healthcare Company $21.7205/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000852157 CMS
Janssen Biotech, Inc. $20.5705/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988333079 CMS
ViiV Healthcare Company $89.6005/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000851505 CMS
ViiV Healthcare Company $329.0005/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000851839 CMS
ViiV Healthcare Company $3,900.0005/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000852073 CMS
ViiV Healthcare Company $56.0005/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000852087 CMS
Gilead Sciences, Inc. $6,000.0005/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035826587 CMS
ViiV Healthcare Company $6.2605/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000851855 CMS
Merck Sharp & Dohme LLC $26.8505/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048786957 CMS
ViiV Healthcare Company $3,900.0005/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000850975 CMS
ViiV Healthcare Company $66.8705/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000851919 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $165,074.49 233
PY2020 $98,833.84 94
PY2021 $65,198.49 82
PY2022 $91,359.68 116
PY2023 $81,872.38 159
PY2024 $92,768.10 132
PY2025 $116,764.66 166

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $82,748.67 18
PY2024 Principal investigator $73,599.00 16
PY2023 Principal investigator $145,431.70 26
PY2022 Principal investigator $125,070.54 35
PY2021 Principal investigator $137,894.22 43
PY2020 Principal investigator $144,307.40 41
PY2019 Principal investigator $155,758.05 50

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $2,283.42 12/31/2025 Non-covered Recipient Entity
Philadelphia Fight Community Health Centers
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis No dispute reported 06/30/2026 1232934540
Principal investigator 1 Gilead Sciences, Inc. $1,149.00 12/23/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220010
Principal investigator 1 Gilead Sciences, Inc. $1,372.00 11/18/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220000
Principal investigator 1 Gilead Sciences, Inc. $1,372.00 10/21/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219990
Principal investigator 1 Gilead Sciences, Inc. $5,096.00 10/14/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219981
Principal investigator 1 Gilead Sciences, Inc. $4,708.00 09/23/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People: Qualitative Insights Into Social and Behavioral Contexts No dispute reported 06/30/2026 1229215164
Principal investigator 1 Gilead Sciences, Inc. $2,744.00 09/16/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219967
Principal investigator 1 Gilead Sciences, Inc. $5,218.00 08/19/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219955
Principal investigator 1 ViiV Healthcare Company $11,231.25 08/14/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
CAPTIVATE (CAB LA FOR PREP UTILIZATION OUTCOMES EXPERIENCE) No dispute reported 06/30/2026 1190319069
Principal investigator 1 Gilead Sciences, Inc. $4,718.00 07/22/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219947
Principal investigator 1 Gilead Sciences, Inc. $1,142.00 06/17/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219937
Principal investigator 1 Gilead Sciences, Inc. $3,306.00 05/20/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219929
Principal investigator 1 Gilead Sciences, Inc. $5,789.00 04/22/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219918
Principal investigator 1 Gilead Sciences, Inc. $1,313.00 04/01/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219907
Principal investigator 1 Gilead Sciences, Inc. $2,514.00 03/18/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219892
Principal investigator 1 ViiV Healthcare Company $14,900.00 03/11/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
CAPTIVATE (CAB LA FOR PREP UTILIZATION OUTCOMES EXPERIENCE) No dispute reported 06/30/2026 1190319071
Principal investigator 1 Gilead Sciences, Inc. $4,816.00 02/19/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219885
Principal investigator 1 Gilead Sciences, Inc. $9,077.00 01/22/2025 Non-covered Recipient Entity
PHILADELPHIA FIGHT
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229219877